RxDoctor Payments Data

Jeremy Warner, DO

Internal Medicine · Corvallis, ORNPI 1992947030

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Edwards Lifesciences at 41.1% of the total. Reporting peaked in 2023 at $142 and has fallen 76.8% since, to $33 in 2024.

$291in general payments, 2019–2025

Across 8 payments — averaging $36.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$120
  • Abiomed$82
  • Novartis$56
  • Pfizer$18
  • Lexicon Pharmaceuticals, Inc.$16
$336,961in research payments, 2019–2025

Across 14 payments — averaging $24,069 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$205K
  • Eli Lilly$132K

What the payments were for

  • Food & beverage$291100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$291 in reported general payments places this provider in the 80th percentile of 1,363 internal medicine providers in Oregon.

See all internal medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$78,527
Medicare patients
1,287
Services billed
1,667

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban222$252,332
EntrestoSacubitril/Valsartan65$85,490
Repatha SureclickEvolocumab80$51,202
XareltoRivaroxaban30$33,256
Metoprolol Succinate328$5,459
Atorvastatin Calcium290$4,504
VascepaIcosapent Ethyl13$4,321
Ezetimibe174$3,919
Rosuvastatin Calcium144$2,376
Carvedilol160$2,286
ClopidogrelClopidogrel Bisulfate110$1,978
Lisinopril112$1,310
Losartan Potassium91$1,155
Amiodarone Hcl46$1,138
Flecainide Acetate13$1,108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$252,332222 claims
NovartisEntresto$56$85,49065 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,363 internal medicine providers in Oregon.

Other internal medicine in Corvallis

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →